299 results match your criteria Microcystic Adnexal Carcinoma

Incidence and trends of cutaneous adnexal tumors in the United States in 2000-2018: A population-based study.

J Am Acad Dermatol 2022 May 4. Epub 2022 May 4.

Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia; Winship Cancer Institute of Emory University School of Medicine, Atlanta, Georgia; Atlanta VA Health Care System, Decatur, Georgia.

View Article and Full-Text PDF

Four calcium signaling pathway-related genes were upregulated in microcystic adnexal carcinoma: transcriptome analysis and immunohistochemical validation.

World J Surg Oncol 2022 May 4;20(1):142. Epub 2022 May 4.

Department of Pathology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, No. 32, West Second Section, First Ring Road, Chengdu, 610072, China.

Background: Microcystic adnexal carcinoma (MAC) is a skin cancer with challenges in diagnosis and management. This study was aimed to detect molecular alterations of MAC and guide its pathologic diagnosis and treatment.

Methods: We performed transcriptome analysis on 5 MAC and 5 normal skin tissues, identified the differentially expressed genes, and verified them by immunohistochemistry. Read More

View Article and Full-Text PDF

Does Immunohistochemistry Add to Morphology in Differentiating Trichoepithelioma, Desmoplastic Trichoepithelioma, Morpheaform Basal Cell Carcinoma, and Microcystic Adnexal Carcinoma?

Appl Immunohistochem Mol Morphol 2022 Apr;30(4):273-277

Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center.

Background: The distinction among cutaneous basaloid neoplasms such as trichoepithelioma (TE), desmoplastic trichoepithelioma (DTE), morpheaform basal cell carcinoma (MBCC), and microcystic adnexal carcinoma (MAC) can be difficult, especially in superficial biopsies. As the treatment plan of each entity is different, accurate characterization is important for appropriate management. While TE and DTE are benign neoplasms with indolent behavior, MBCC and MAC are typically locally aggressive. Read More

View Article and Full-Text PDF

Impact of expert pathology review in skin adnexal carcinoma diagnosis: Analysis of 2573 patients from the French CARADERM network.

Eur J Cancer 2022 03 30;163:211-221. Epub 2022 Jan 30.

Dermatology and Dermatopathology, University Hospital and Faculty of Medicine, University of Strasbourg, France.

Purpose: To prospectively assess the impact of expert pathological review of skin adnexal carcinoma diagnosis in France.

Methods: From 2014 to 2019, 2573 samples from patients with newly diagnosed or suspected skin adnexal carcinomas were reviewed prospectively by expert pathologists through the national CARADERM (CAncers RAres DERMatologiques) network. Changes in diagnosis between referral and expert review were analysed regarding their potential impact on patient care or prognosis. Read More

View Article and Full-Text PDF

Matrix Metalloproteinase 28-Bearing Microcystic Adnexal Carcinoma on the Back.

Case Rep Oncol 2021 Sep-Dec;14(3):1773-1778. Epub 2021 Dec 13.

Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Although microcystic adnexal carcinoma (MAC) recurs and expands locally without metastases to the lymph nodes and other organs, its biological behavior remains unknown. In this report, a case of a giant MAC on the back treated with radical excision and curative radiation therapy and its characteristic dermoscopic findings are presented. In addition, immunohistochemical staining showed the expression of matrix metalloproteinase (MMP) 28 on the tumor cells and MMP12 and periostin in the stroma. Read More

View Article and Full-Text PDF
December 2021

A review of Mohs micrographic surgery for skin cancer. Part 1: Melanoma and rare skin cancers.

Clin Exp Dermatol 2022 May 22;47(5):833-849. Epub 2022 Feb 22.

Department of Dermatology, Manor Hospital, Walsall Healthcare NHS Trust, Walsall, UK.

Mohs micrographic surgery (MMS) is a precise and effective method commonly used to treat high-risk basal cell carcinoma and squamous cell carcinoma on the head and neck. Although the majority of evidence for MMS relates to keratinocyte cancers, there is published evidence for other types of skin cancer. This review aims to discuss the evidence for using MMS to treat six different types of skin cancer [malignant melanoma, lentigo maligna, dermatofibrosarcoma protuberans, atypical fibroxanthoma (AFX), microcystic adnexal carcinoma and pleomorphic dermal sarcoma (PDS)] particularly in the context of survival rates and cancer recurrence. Read More

View Article and Full-Text PDF

Microcystic adnexal carcinoma of the scalp treated with surgical resection along with chemoradiation: A case report and review of the literature.

Saudi J Biol Sci 2021 Dec 5;28(12):7117-7124. Epub 2021 Aug 5.

Department of Otolaryngology - Head and Neck Surgery, King Abdulaziz University, Jeddah, Saudi Arabia.

Microcystic adnexal carcinoma (MAC) is an infiltrative rare cutaneous neoplasm for which there are no consensus management guidelines because of the paucity of evidence-based practice; hence, the utility of their management is based only on previously published case reports. We report a case of a scalp lesion that was successfully treated using a combination of surgical resection, chemotherapy, and radiotherapy. Read More

View Article and Full-Text PDF
December 2021

Emerging therapies for rare cutaneous cancers: A systematic review.

Cancer Treat Rev 2021 Nov 16;100:102266. Epub 2021 Aug 16.

Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, United States.

Background: Rare cutaneous cancers require early management given their aggressive nature; however, few therapeutic options exist for managing these rare cancers.

Objective: To identify emerging therapies for extramammary Paget's disease, Merkel cell carcinoma, sebaceous gland carcinoma, microcystic adnexal carcinoma, Kaposi sarcoma and cutaneous angiosarcoma.

Methods: A systematic review was conducted using PubMed database from October 2010 to October 2020. Read More

View Article and Full-Text PDF
November 2021

[Management of malignant adnexal neoplasms of the skin].

Hautarzt 2021 Jul 17;72(7):619-632. Epub 2021 Jun 17.

Klinische Kooperationseinheit für Dermatoonkologie des Deutschen Krebsforschungszentrums (DKFZ) Heidelberg, Mannheim, Deutschland.

Malignant adnexal neoplasms of the skin are a heterogeneous group of rare malignancies with eccrine, apocrine, sebaceous and follicular differentiation. Essential clinical practice recommendations for the overall management of these cancers are presented. Moreover, specific evidence-based findings according to diagnosis, therapy and follow-up of porocarcinoma, sebaceous carcinoma and microcystic adnexcarcinoma will be explained. Read More

View Article and Full-Text PDF

A well-defined, firm, yellowish-orange alopecic plaque with multiple whitish papules on the scalp.

Clin Exp Dermatol 2021 Oct 18;46(7):1358-1361. Epub 2021 May 18.

Departments of, Departments of, Dermatology, Keio University School of Medicine, Tokyo, Japan.

View Article and Full-Text PDF
October 2021

Desmoplastic Trichoepithelioma With Pseudocarcinomatous Hyperplasia: A Folliculosebaceous Neoplasm in Young Persons.

Am J Dermatopathol 2021 Nov;43(11):788-793

UCSF Dermatopathology and Oral Pathology Service, University of California San Francisco, San Francisco, CA.

Abstract: Pseudocarcinomatous desmoplastic trichoepithelioma (PDTE) features verrucous squamous epidermal hyperplasia with a jagged undersurface overlying cords of follicular germinative cells in a fibrotic stroma. To date, only 5 cases have been reported. We identified 7 new PDTEs from 2 institutions and reviewed their clinical manifestations and immunohistochemical profile. Read More

View Article and Full-Text PDF
November 2021

Microcystic adnexal carcinoma of the glabella in a liver transplant recipient.

JAAD Case Rep 2021 Apr 4;10:126-129. Epub 2020 May 4.

Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.

View Article and Full-Text PDF

Microcystic Adnexal Adenoma: The Benign Counterpart of Microcystic Adnexal Carcinoma.

Am J Dermatopathol 2021 Nov;43(11):835-837

Department of Dermatology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; and.

Abstract: Microcystic adnexal carcinoma (MAC) is a low-grade malignant neoplasm of slow growth and low metastatic potential, but locally aggressive. Architecturally, MAC is usually a poorly circumscribed neoplasm that tends to extend deeply into the dermis and subcutaneous tissue. We present here a lesion in which the histopathologic study showed a well-demarcated nodular lesion involving the mid dermis and composed of small cystic keratinous structures, solid aggregates of pale squamous cells without cytologic atypia and ductal structures. Read More

View Article and Full-Text PDF
November 2021

Mohs Surgery Outside Usual Indications: A Review.

Acta Dermatovenerol Croat 2020 Dec;28(7):210-214

Pedro Rodríguez-Jiménez, MD, Dermatology Department, Hospital Universitario de la Princesa, Madrid, Calle Diego de Leon 62, 28006 Madrid, Spain;

The body of literature supporting the use of Mohs micrographic surgery (MMS) in tumors outside the main indications (basal cell carcinoma, squamous cell carcinoma, dermatofibrosacroma protuberans, lentigo maligna) is constantly growing, but it is still based on case reports, case series, or at best institutional case series that focus on a single malignancy. Our aim in this review was to assess use of MMS in an array of rare tumors outside the usual indications. A review was performed using the MEDLINE database and the search engine ClinicalKey®. Read More

View Article and Full-Text PDF
December 2020

Microcystic Adnexal Carcinoma with Xanthomatous Reaction.

Acta Derm Venereol 2021 Apr 26;101(4):adv00436. Epub 2021 Apr 26.

Department of Dermatology, Kagoshima University, 890-8520 Kagoshima, Japan. E-mail:

View Article and Full-Text PDF

Expression of Hedgehog signalling molecules in microcystic adnexal carcinoma.

Clin Exp Dermatol 2021 Aug 1;46(6):1052-1057. Epub 2021 May 1.

Institute for Prevention and Occupational Medicine of the German Social Accident Insurances, Ruhr-University Bochum (IPA), Bochum, Germany.

Background: Microcystic adnexal carcinoma (MAC) is a rare skin neoplasm that has not been characterized on a molecular basis.

Aim: To assess expression profiles of Hedgehog (HH) signalling molecules in MAC and control tumours.

Methods: Immunohistochemistry was performed for Sonic Hedgehog (SHH), Indian Hedgehog (IHH), Patched 1 (PTCH1) and Smoothened (SMO) on patient MAC tissue (n = 26) and control tumour tissue, including syringoma (SyG; n = 11), trichoepithelioma (TE; n = 11) and basal cell carcinoma (BCC; n = 12) tissues. Read More

View Article and Full-Text PDF

Local Recurrence Rates of Skin Tumors After Resection With Complete Circumferential Peripheral and Deep Margin Assessment-Identification of High-Risk Entities.

Dermatol Surg 2021 02;47(2):e31-e36

All authors are affiliated with the Department of Dermatology, Eberhard-Karls-UniversityTübingen, Tübingen, Germany.

Background: The local recurrence rates of malignant skin tumors after micrographic controlled surgery using complete circumferential peripheral and deep margin assessment (CCPDMA) are reported to be low. However, in daily practice, tumor entities with a significantly higher recurrence rate are found.

Objective: The aim of the investigation was to identify these high-risk tumors to develop approaches for risk stratification. Read More

View Article and Full-Text PDF
February 2021

Facial microcystic adnexal carcinoma - treatment with a "jigsaw puzzle" advancement flap and immediate esthetic reconstruction: A case report.

World J Clin Cases 2021 Jan;9(3):607-613

Department ofPlastic Surgery, Peking Union Medical College Hospital, Beijing 100730, China.

Background: Microcystic adnexal carcinoma (MAC) is a rare malignant tumor of the skin that is commonly found on the face. It grows slowly and has a low mortality rate. However, for various reasons, including strong histological invasiveness, clinical inexperience and inadequate procedure design, immediate or permanent facial deformity may occur after surgical operations. Read More

View Article and Full-Text PDF
January 2021

MOHS micrographic surgery for head and neck nonmelanoma skin cancer: An approach for ENT surgeons.

Dermatol Ther 2021 01 21;34(1):e14661. Epub 2020 Dec 21.

FMUP-Faculty of Medicine, University of Porto, Porto, Portugal.

Surgery is the main approach for skin cancer, with Mohs micrographic surgery (MMS) allowing the highest cure rates, best esthetics and superior functional outcomes. Ear, nose, and throat (ENT) surgeons are often challenged with patients presenting skin cancer, needing appropriate expertise to its adequate management. This paper highlights the most important aspects of MMS, enabling ENT surgeons to become familiar with its fundamental aspects. Read More

View Article and Full-Text PDF
January 2021

Microcystic adnexal carcinoma of the head and neck: Characteristics, treatment, and survival statistics.

Dermatol Ther 2021 01 3;34(1):e14559. Epub 2020 Dec 3.

Dermatology and Pathology, Rutgers New Jersey Medical School, Newark, New Jersey, USA.

Studies on microcystic adnexal carcinoma (MAC) survival rates have been limited. This effort examines the association of patient demographics, treatment modalities, and tumor stage with overall survival (OS) in patients with MAC of the head and neck. All cases of MAC with primary sites of the skin of the head and neck, confirmed histologically, and diagnosed from 2004 to 2016 in the National Cancer Database, were analyzed. Read More

View Article and Full-Text PDF
January 2021

Sequencing of Sclerosing Microcystic Adenocarcinoma Identifies Mutational Burden and Somatic Variants Associated With Tumorigenesis.

Anticancer Res 2020 Nov;40(11):6375-6379

Division of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, CT, U.S.A.

Background/aim: Sclerosing microcystic adenocarcinoma (SMA) is a rare oral cavity neoplasia, histologically resembling microcystic adnexal carcinoma (MAC) of the skin. Only nine SMA cases have been reported in the literature, frequently in the context of immunosuppression; SMA has not been recognized in the most recent WHO tumor classification. We sought to identify potential molecular mechanisms of tumorigenesis in a case of SMA relative to those known for MAC. Read More

View Article and Full-Text PDF
November 2020

An atypical presentation of extensive centrofacial microcystic adnexal carcinoma responding to radiation: A case report and review of the literature.

SAGE Open Med Case Rep 2020 26;8:2050313X20953114. Epub 2020 Sep 26.

Division of Dermatology, University of Saskatchewan, Regina, SK, Canada.

Microcystic adnexal carcinoma is a rare cutaneous neoplasm believed to arise from pluripotent keratinocytes capable of adnexal differentiation. Due to its insidious growth and appearance, diagnosis is often delayed. A deep incisional or excisional biopsy for histopathology is the gold standard for diagnosis. Read More

View Article and Full-Text PDF
September 2020

Desmoplastic Trichoepithelioma: Histopathologic and Immunohistochemical Criteria for Differentiation of a Rare Benign Hair Follicle Tumor From Other Cutaneous Adnexal Tumors.

Cureus 2020 Aug 12;12(8):e9703. Epub 2020 Aug 12.

Pathology, South Bend Medical Foundation, South Bend, USA.

Desmoplastic trichoepitheliomas (DTEs) are benign cutaneous neoplasms that originate from the hair follicle and exhibit a preference for the facial region. This type of neoplasm is characterized by accelerated growth, with vigorous histologic and immunohistochemical features that may be confused with other skin cancers. Thus, the objective of this study is to establish a definitive diagnosis that can be widely used. Read More

View Article and Full-Text PDF

Microcystic adnexal carcinoma with germinative follicular differentiation.

J Cutan Pathol 2021 Jan 5;48(1):123-127. Epub 2020 Nov 5.

Dermatology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.

Microcystic adnexal carcinoma (MAC) is a low-grade adnexal carcinoma with controversial lines of differentiation. We present here an example of MAC showing histopathologic findings of germinative follicular differentiation in the form of solid aggregates of trichoblastoma intermingled with neoplastic aggregates of MAC. Immunohistochemical findings, showing positivity for PHLDA1 and negativity for BerEp4 in neoplastic aggregates of trichoblastoma, also supported a germinative follicular differentiation. Read More

View Article and Full-Text PDF
January 2021

Mohs micrographic surgery: a treatment method for many non-melanocytic skin cancers.

Dermatol Online J 2020 Apr 15;26(4). Epub 2020 Apr 15.

Department of Dermatology, Baylor College of Medicine, Houston, TX.

Mohs micrographic surgery (MMS) is a breakthrough surgical technique that has changed the management of neoplasms in dermatology. Through continued practice and evolution, MMS now can successfully treat a variety of rare non-melanocytic cutaneous malignancies for which achieving remission and the optimal aesthetic result after surgery was previously challenging. Mohs micrographic surgery has utility for conditions besides melanoma. Read More

View Article and Full-Text PDF

Periocular skin cancer: Diagnosis and management.

Dis Mon 2020 Oct 27;66(10):101046. Epub 2020 Jun 27.

Division of Ophthalmology, NorthShore University Health System, 2050 Pfingsten Rd., Ste. 280, Glenview, IL 60026, United States; Department of Ophthalmology and Visual Science, University of Chicago, Chicago, IL, United States. Electronic address:

The periocular region sees high rates of cancer compared to the rest of the body and can be affected by several unique tumors. Treatment typically involves surgical excision, although adjunctive therapies and prognosis vary depending on the diagnosis. Basal cell carcinoma (BCC) is the most common malignancy affecting this region and should be excised promptly. Read More

View Article and Full-Text PDF
October 2020

Determinants of Microcystic Adnexal Carcinoma Management and Outcomes in British Columbia.

J Cutan Med Surg 2020 Sep/Oct;24(5):536-537. Epub 2020 Jun 25.

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

View Article and Full-Text PDF